Introduction 1
Macrophage plasticity provides tailored homeostatic, immunologic and reparative mechanisms in 2 a wide-range of tissues (1, 2) . Their transcriptional, epigenetic and functional versatility allow 3 macrophages to conform to tissue-and disease-specific factors, resulting in phenotypes 4 indicative of the type of tissue and physiologic state (3) (4) (5) (6) (7) (8) (9) . While macrophages are a unifying 5 feature in chronic human diseases such as atherosclerosis, autoimmunity and granulomas (2, 10, 6 11), little is known about macrophage phenotypes in the context of human tissue pathology-7 particularly at the single-cell level. Furthermore, while in vitro studies have provided valuable 8 insights into the range of macrophage polarization states (12, 13) , the relevance of these well- 9 characterized responses has been difficult to document in human tissues. 10 A precise understanding of human tissue macrophages may enable more effective 11 therapeutic decisions for inflammatory diseases, where it has often been difficult to discern 12 which molecular pathways to target. For example, in inflammatory bowel diseases cytokines 13 such as IL-17 and IFN-γ have been implicated in the pathophysiology, yet blockade of these 14 factors have produced variable results and in some cases worsens symptoms, whereas anti-TNF 15 therapies are commonly effective (14) . In the autoimmune disease rheumatoid arthritis (RA) 16 nonsteroidal anti-inflammatory drugs (NSAIDS) treat pain and components of inflammation, but 17 for unclear reasons do not curb joint erosion (15), whereas anti-TNF therapies have proven 18 highly effective on both fronts. Macrophages, as innate immune cell types common to tissues 19 that are heavily influenced by microenvironmental factors, could serve in affected tissues as 20 indicators of disease pathways and as targets of tailored treatments. Furthermore, in cancer, new 21 therapeutic strategies not only disrupt support of tumor growth and metastasis by macrophages, 22 but aim to repolarize them towards pro-resolution anti-tumor states (16, 17) . To develop such 23 5 therapeutics for autoimmune and inflammatory conditions, an in-depth classification is needed 1 for tissue macrophages and how medications redirect them, amidst the complexity of tissue and 2 disease signals, towards beneficial or a differing yet pathologic state. 3 In the chronically inflamed RA joint tissue, macrophages are understood to be a source of 4 TNF, a well-established driver of . However, the precise nature and variety of 5 macrophages within the RA synovium is not yet defined, nor is the cumulative impact of 6 surrounding intercellular interactions and medication-induced perturbations on macrophage 7 responses in RA tissue pathology. To define the spectrum of macrophage phenotypes in a human tissue affected by autoimmunity, 13 as reported (22), we sorted synovial cells from ten RA patients and two osteoarthritis (OA) 14 disease control patients by CD14 + cell surface protein expression and applied single-cell RNA 15 sequencing (scRNA-seq, CEL-Seq2). After stringent quality control filtering, 940 CD14 + single 16 cells clustered into four major CD14 + synovial cell subsets based on Canonical Correlation 17 Analysis (CCA) as described (22) (Fig. 1A) . Cells from all four clusters expressed genes that 18 define the myeloid lineage, such as CD68, CD163 and C1QA and based on their high levels of 19 CD14 (Fig. S1A ), we designated these cells macrophages rather than dendritic cells (7, 23) . 20 Clusters 1 and 2 contained the majority of the CD14 + synovial cells (45% and 30%, respectively) 21 and the largest number of genes that distinguished them from the other clusters, such as PLAUR 22 and HBEGF for Cluster 1 (referred to as the 'Cluster 1 HBEGF + ) and ADORA3 and MERTK for 23 6 Cluster 2 ( Fig. 1B, Fig. S1B, 125 and 193 genes >2-fold, respectively). Cluster 3 appeared less 1 well defined by positive markers, whereas Cluster 4 had robust markers including IFN-target 2 genes such as IFI6 and IFI44L and herein is referred to as the 'IFN/STAT' cluster ( Fig. 1B, Fig. 3 S1B). 4 To estimate the abundance of the macrophage clusters in RA tissue, we sorted CD14 + 5 synovial cell populations from 18 RA and 14 OA patients and analyzed them using bulk RNA-6 seq (~1,000 CD14 + cells from each patient) as reported (22) . We detected 1,726 genes with 7 distinct expression patterns between the disease states (FDR adjusted p value <0.1). Enriched in 8 RA CD14 + cell populations, we detected elevated levels of genes and pathways that associate 9 with RA disease such as TNF, STAT1 and STAT4 and the response to TNF, Interferon and 10 Inflammation (Gene Set Enrichment Analysis (GSEA)) ( Fig. 1C , left and right panel, 11 respectively) (24-27). Overlaying the RA versus OA comparison with markers from each of the 12 single-cell clusters, we found that genes defining Cluster 1 HBEGF + and Cluster 4 IFN/STAT 13 were consistently more abundant in RA CD14 + populations, suggesting an enrichment of these 14 cell subsets in RA ( Fig. 1D ). Cluster 2 genes were in higher ratios in OA tissues, while Cluster 3 15 markers showed no consistent association with either disease (Fig. 1D ). Furthermore, RA CD14 + 16 populations were positively enriched in genes sets from Cluster 1 HBEGF + and Cluster 4 17 IFN/STAT while negatively enriched in Cluster 2 genes (GSEA, FDR adjusted p-value 18 <0.001)( Fig. 1E , light grey bars). 19 To identify factors from the microenvironment that shape synovial macrophage 20 phenotypes, the synovial CD14 + single-cell gene sets were compared to human blood-derived 21 macrophages activated by diverse stimuli (Fig. 1E , colored bars, ranked gene lists). Cluster 1 22 HBEGF + and Cluster 4 IFN/STAT genes were positively enriched in pro-inflammatory M1-like expressed in >30% of cells). Hypergeometric test: ***,* represent p <10 -6 , <10 -3 , respectively. 10 Right: Number of cluster genes higher in RA or OA bulk comparison or not significant (ns) 11 (FDR adjusted p-value < 0.1). (E) GSEA using the CD14 + single-cell markers as Gene Sets and 12 ranked gene lists from human blood-derived macrophages exposed to various stimuli (colored macrophage genes induced by TNF and anti-correlated with the IL-4 driven M2 anti-1 inflammatory phenotype, indicating these two macrophage subsets are activated by pro-2 inflammatory factors ( Fig. 1E , red v yellow bars). Conversely, Cluster 2 genes were negatively 3 enriched for TNF-induced inflammatory response suggesting an anti-inflammatory phenotype, 4 while the lack of enrichment with the IL-4 induced M2 state potentially indicates a novel tissue 5 macrophage phenotype. The limited number of Cluster 3 positive markers did not significantly 6 associate with any of the stimulated macrophage states. 7 As the most abundant cell type in the RA synovium (28) ( Fig. S2A ), synovial fibroblasts 8 can evoke large shifts in macrophage gene expression profiles (29). Importantly, the combination 9 of synovial fibroblasts together with TNF (TNF+Fib) generated a macrophage phenotype that 10 aligned with Cluster 1 HBEGF + macrophages more than the other stimuli ( Fig. 1E ). This was 11 unlikely due to an additive effect that exacerbates the TNF response, as synovial fibroblasts and 12 TNF can independently induce robustly opposing effects, for example in Cluster 4 genes (Fig. 13 1E). Thus, we posited that the abundant Cluster 1 HBEGF + macrophages identified by single-cell 14 analyses from affected human tissue are driven by the combination of tissue-specific factors 15 from the resident synovial fibroblasts and inflammatory signals such as TNF found in the RA 16 synovium. 17 Consistent with enrichment in RA, the CD14 + Cluster 1 HBEGF + single-cells expressed 18 high levels of classic inflammatory genes like IL1B and low levels of M2-associating genes such 19 as MERTK (Fig. 1B , F)(13). However, Cluster 1 HBEGF + cells were also distinctively high in 20 the expression of genes such as HBEGF (Heparin Binding EGF Like Growth Factor) and 21 PLAUR (plasminogen activator, urokinase receptor) ( Fig. 1F ), which have largely been reported 22 as marking anti-inflammatory phenotypes or cells derived from a combination of pro-and anti-23 10 inflammatory triggers (30, 31) . Considering this distinct program ( Fig. 1G ), we designate Cluster 1 1 macrophages 'HBEGF + inflammatory macrophages'. 2 Importantly, in an independent study using a droplet-based single-cell RNA-seq platform 3 (Drop-seq) applied to five RA patient synovial tissues ( Tissue-resident synovial fibroblasts shape HBEGF + inflammatory macrophages 12 To further define the HBEGF + inflammatory phenotype, we compared the transcriptome of 13 macrophages exposed to TNF and synovial fibroblasts versus TNF alone. In a transwell co-14 culture system where both cell types were exposed to TNF (24h, n=4 donors), synovial 15 fibroblasts altered the expression of 3,709 macrophage genes (FDR adjusted p value < 0.1) ( These data suggest that in the RA synovium, chronic exposure to the pro-inflammatory 8 environment results in heightened synovial fibroblast production of prostaglandins that, together 9 with inflammatory factors, drive macrophages towards a state distinct from classical M1 and M2 10 polarization. Unique transcriptional regulators, cell surface markers, metabolic pathways and 11 chromatin modifications mark this HBEGF + inflammatory state. 12 13 HBEGF + inflammatory macrophages promote fibroblast invasiveness 14 To examine how HBEGF + inflammatory macrophages may impact RA pathology, we focused on 15 their intercellular relationship with synovial fibroblasts. In an RNA-seq analysis, exposure to 16 HBEGF + inflammatory macrophages altered 855 synovial fibroblast genes (FDR adjusted p-17 value <0.1), including induction of IL11, LIF, CSF3 (GCSF), IL33, IL6 and PLAU (Fig. 3A) . 18 Pathway analyses revealed an upregulated EGFR response in the fibroblasts, observed with two 19 gene sets (one induced by EGFR ligands and a second blocked by an EGFR inhibitor)( Fig. 3B ). 20 Similar to the gene expression changes, we also detected increased GCSF and IL-33 protein 21 secretion in the presence of HBEGF + macrophages (Fig. 3C ). The increased molecular 22 production of neutrophil chemoattractants and growth factors, such as GCSF, led us to 23 15 investigate potential cellular effects of HBEGF + inflammatory macrophages. We report 1 neutrophil accumulation-a well-documented feature of RA joint fluid (33, 34) following co-2 culture of HBEGF + macrophages with synovial fibroblasts (Fig. S4A ). Lastly, we found the 3 expression of GCSF and IL-33 was sensitive to EGFR inhibition (AG-1478 (AG))( Fig. 3D ), 4 further implicating EGFR involvement in this inflammatory macrophage-fibroblast crosstalk 5 system and identifying an additional therapeutic avenue to target HBEGF + macrophage driven 6 inflammation. 7 To further understand the EGFR-mediated gene expression in the synovial fibroblasts, we 8 investigated the levels of EGF ligands in this system. Synovial fibroblasts expressed only trace 9 amounts of seven EGF ligands with no change in response to TNF and HBEGF + macrophages 10 ( Fig. S4B ). In notable contrast, macrophages induced HBEGF and a second EGF ligand EREG 11 (epiregulin) upon combined exposure of TNF and synovial fibroblasts ( Fig. S4B ). While EREG 12 expression in the blood-derived macrophage system was higher than HBEGF (Fig. S4B ), we 13 have placed more emphasis on HBEGF as the RA patient synovial macrophages exhibit 14 considerably higher expression of HBEGF (Fig. 1B) . For EGF receptor expression, synovial 15 fibroblasts expressed two subunits (EGFR and ERBB2), while neither blood-derived 16 macrophages nor RA synovial macrophages expressed EGFR subunits ( Fig. S4C, D) . 17 Considering these data, we posit synovial fibroblast EGFR responses correspond to production 18 of EGF ligands by fibroblast-entrained inflammatory HBEGF + macrophages. 19 EGFR signaling is a robust regulator of fibroblast motility (35) and in RA, synovial 20 fibroblasts invade and destroy cartilage and bone (36) (37) (38) (39) . Thus, we next tested whether the fibroblast invasiveness that was mitigated by EGF receptor inhibition ( Fig. 3E, F) . These data 1 demonstrate that the HBEGF + macrophage-dependent EGFR response may promote pathologic 2 fibroblast-mediated and pannus-associated tissue destructive behaviors in RA joints. 3 4 RA medications target HBEGF + inflammatory macrophage polarization 5 We next examined how clinically effective RA medications impact the polarization of HBEGF + 6 inflammatory macrophages, using human blood-derived macrophages exposed to TNF and 7 synovial fibroblasts. In comparison to macrophages exposed only to TNF, the presence of 8 synovial fibroblasts substantially altered the impact of most medications (Fig. S5A ). For 9 example, the majority of auranofin targets were lost when macrophages were polarized towards 10 the HBEGF + phenotype (1,300 genes, 67%) ( Fig. S5A , blue versus yellow). In contrast, several 11 medications gained more than 1,000 gene targets in HBEGF + inflammatory macrophages, 12 including naproxen (Nap) and leflunomide (active metabolite A77) ( Fig. S5A) . Thus, the 13 pronounced impact synovial fibroblasts confer onto macrophages includes alteration of drug 14 responsiveness. 15 Several medications reversed a large portion of fibroblast-induced effects (~1,000 genes), 16 suggesting the efficacy of these treatments could involve suppressed generation of HBEGF + 17 inflammatory macrophage in RA synovium (Fig. 4A, black) . This included leflunomide (A77), 18 dexamethasone (steroid), naproxen and Triple therapy (Tri, hydroxychloroquine + sulfasalazine 19 + methotrexate)( Fig. 4A, black) . As naproxen inhibits COX enzyme-mediated prostaglandin 20 production and affected the majority (~80%) of genome-wide fibroblast-mediated effects ( inflammatory macrophages, however, resulted in at least two functionally distinct states. 1 Naproxen, for example, blocked the prostaglandin arm driving HBEGF + inflammatory 2 macrophages, but still permitted TNF polarization of the macrophages towards an M1-like pro-3 inflammatory phenotype, which presumably also functions pathologically in RA synovium (Fig.   4 S5A-C). Medications like dexamethasone were capable of blocking large portions of both 5 programs (Fig. S5A ). This result highlights the importance of understanding the resulting 6 phenotypes of macrophages targeted by medications, particularly in complex tissue settings 7 where multiple factors could redirect macrophages towards a differing yet pathologic state. To examine the impact of therapeutically targeting HBEGF + macrophages in RA joints, we 12 directly assayed synovial tissue from RA patients with definitive RA diagnoses (40, 41) and 13 extensive joint inflammation confirmed by histologic scoring (42, 43) (Table S1, n=8). 14 Specifically, in an ex vivo tissue assay, synovium was dissociated into cell suspensions (44) and 15 cultured with FDA-approved RA medications (Fig. 4B ). Similar to the seminal assays that laid 16 the precedent for anti-TNF therapies in RA (45), as well as the documented clinical responses 17 (46, 47) , exposure to anti-TNF antibodies (αTNF, adalimumab) suppressed production of the 18 inflammatory mediator IL-1β (Fig. 4C ). Furthermore in this assay, the JAK inhibitor tofacitinib 19 imparted striking reductions in genome-wide IFNα responses and protein levels for the 20 JAK/STAT target CXCL10 (IP10) (Fig. 4C ). Notably in this tissue explant assay, anti-inflammatory therapies such as anti-TNF, 1 tofacitinib and dexamethasone inhibited the HBEGF + inflammatory synovial macrophage 2 Cluster 1 gene set (Fig. 4D) . Conversely, the panel of anti-inflammatory medications upregulated 3 the Cluster 2 gene set (with one exception, A77/leflunomide) (Fig. 4D) , further suggesting 4 Cluster 2 cells possesses anti-inflammatory features, which also aligns with high levels of anti-5 inflammatory genes MERTK, TGFBI and MARCO (48-50) (Fig. 1F, Fig. S5D ). Tofacitinib was 6 the most potent inhibitor of the Cluster 4 'IFN/STAT' gene set, further implicating a robust 7 JAK/STAT response in this RA-associated macrophage subset (Fig. 4C) . Interestingly, the 8 JAK/STAT response in Cluster 4 was induced by naproxen, as shown by enrichment in Cluster 4 9 genes and an elevated CXCL10/IP10 protein production in naproxen-treated RA synovial cells 10 ( Fig. 4D-F ). This correlated with reduced prostaglandins levels with naproxen and is in accord 11 with the established inhibitory effects of prostaglandins on IFN responses (51-53). 12 To test for evidence of the crosstalk module we have identified between HBEGF + 13 inflammatory macrophages and synovial fibroblast EGFR responses (Figs. 2, 3) , we further 14 examined the effects of naproxen in our tissue explant system. In addition to blocking 15 prostaglandin levels in the RA synovial explants and reducing HBEGF expression ( Fig. 4G ), 16 naproxen also reduced GCSF (CSF3) secretion, indicating a decoupling of the macrophage-17 fibroblast circuit (Fig. 4H ). Importantly, as mentioned above and in Fig. S5 and B , naproxen 18 does not interfere with TNF-mediated effects and thus despite dampening prostaglandin levels in 19 the tissue assay (Fig. 4F) , naproxen treatment did not suppress IL-1b protein production in the ex 20 vivo synovial cell assay (data not shown). TNF blockade, however, was effective in blocking 21 HBEGF expression, as well as, IL-1b and GCSF protein levels (Fig. 4C, D) and thereby derails 22 generation of both the HBEGF + inflammatory macrophages-synovial fibroblast axis and pro-1 inflammatory M1-like macrophages (Fig. 4I ). 2 To directly assay EGFR-dependent fibroblast gene expression changes consistent with 3 HBEGF + inflammatory macrophage influence, we introduced an EGFR inhibitor into the ex vivo 4 assay. Importantly, the EGFR inhibitor reversed the majority of the synovial fibroblast gene 5 expression effects elicited by HBEGF + inflammatory macrophages (77%), including a 6 suppression of CCL20, CSF3, LIF, IL33, IL11, and PLAU (Fig. 4J, 3A) . Together, these data 7 provide evidence within patient tissues for the crosstalk module we identified between HBEGF + 8 inflammatory macrophages and tissue-resident fibroblasts and furthermore indicates blockade of 9 EGFR responses may provide a non-immunosuppressive therapeutic approach for RA. Challenges in treating autoimmune and inflammatory disorders have led to strategies including 13 administering medications sequentially until one is found to improve clinical symptoms. In an 14 effort to improve a priori knowledge of which medication will be most effective, we have taken 15 into consideration the complexity of cellular interactions in affected tissues and identified a 16 population of HBEGF + inflammatory macrophages in inflamed RA joints and delineated their 17 deterministic tissue-resident and disease-specific factors. Furthermore, we have identified 18 medications that successfully interfere with the generation of these macrophages and the support 19 they provide towards fibroblast invasiveness, which contributes to irreversible joint destruction 20 in RA. 21 The crosstalk mechanisms and functional output between macrophages and fibroblasts in 22 the RA tissue environment differ from other pathologic states driven by these two cell types. In 23 24 fibrosis, macrophages and fibroblasts drive excessive collagen deposition blocking tissue 1 function in part by static physical barriers rather than invasion and erosion (2, 54, 55) . We find in 2 RA, fibroblast products such as prostaglandins combine with chronic inflammatory signals such 3 as TNF to polarize macrophages into a state that is distinct from inflammatory M1, anti-4 inflammatory wound healing M2 and pro-fibrotic TGFβ-expressing macrophages. The RA-5 enriched HBEGF + inflammatory macrophages produce a defined subset of inflammatory 6 products such IL-1 and the EGF growth factors HBEGF and epiregulin. As HBEGF + 7 inflammatory macrophages subsequently induce invasiveness in synovial fibroblasts (Fig. 3F ), 8 we classify them as 'pro-invasive macrophages'. 9 While leukocyte-derived growth factors have emerged as critical components in tissue 10 homeostasis and repair (1, 56), our data uncover a pathologic correlate. In the RA tissue 11 environment, macrophage-produced EGF ligands lead to EGFR-dependent synovial fibroblast 12 invasiveness and GCSF production concomitant with enhanced neutrophil accumulation ( Fig.   13 3)-dominant features of RA joint pathology (33, 34, 37) . In inflammatory arthritis in vivo 14 models, disease progression is driven by EGF ligands, EGF receptor activity and the enzyme 15 iRhom2, which mediates release of both TNF and HBEGF from immune cells (57-60). Our data 16 provide relevance to these findings in human disease and a mechanistic understanding of the 17 cellular crosstalk program involving growth factors in RA joints. Furthermore, considerable 18 evidence implicates TNF and HBEGF as pathologic drivers of kidney disease in the autoimmune 19 condition lupus (61, 62). Thus, linked TNF and EGFR responses may be a unifying and 20 targetable feature in tissues affected by disparate autoimmune conditions. 21 Using perturbations relevant to human disease, namely FDA-approved medications, we 22 have detailed the disruption of intercellular interactions in patient samples and the resulting 23 25 phenotypes, thereby gaining insights into the complex consequences of medication in RA joint 1 tissue. In particular, our data has yielded insights into a longstanding question of why anti-2 inflammatory COX inhibitors known as NSAIDs are not "disease-modifying" in RA (15). Our 3 data suggest NSAIDs block the prostaglandin-mediated arm in HBEGF + inflammatory 4 polarization, but still permit macrophage TNF responses (Fig. 4I, Fig. S5B-C) . Thus, NSAID 5 therapy in RA likely redirects HBEGF + inflammatory macrophages towards a classic pro-6 inflammatory M1-like phenotype, which would presumably perpetuate inflammation albeit 7 through a different pathway. In that regard, NSAIDS may best be used in combination with 8 medications like anti-TNFs, in order to target two arms of HBEGF + inflammatory macrophage 9 polarization. However COX inhibition by naproxen also proved problematic in the other RA- RNA-seq and bulk RNA-seq datasets were integrated based on genes that maximized the 6 correlation between the two datasets. The correlated canonical variates were then used to 7 construct a nearest neighbor network thereby generating clusters that are verified to be present in 8 the bulk data. Using the four clusters identified from the CCA method, the top ten canonical 9 coordinates were used to generate a Euclidean distance matrix for tSNE visualization using a 10 perplexity parameter of 40. Positive and negative cluster markers were identified using the 11 Wilcoxon rank sum test with a Bonferroni correction for multiple testing. The CD14+ synovial single-cell data generated by the AMP consortium is housed at 5 http://immport.org with the study accession numbers SDY998 and SDY999. 
